石四藥(02005.HK):治療高血壓藥物獲藥監局藥品生產註冊批件
石四藥集團(02005.HK)公布,治療高血壓藥物關纈沙坦氨氯地平片(Ⅰ)(80mg:5mg),已取得國家藥監局的藥品生產註冊批件,屬於化學藥品第4類,視同通過一致性評價。
纈沙坦氨氯地平片(Ⅰ)主要用於治療原發性高血壓及用於單藥治療不能充分控制血壓的患者。
集團指,該藥物是唯一一個進入國家基本藥物目錄的單片複方降壓藥,也是集團開發的複方固體製劑當中首個獲批產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.